Drugs in MeSH Category Neuroprotective Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	207308-001	Jan 8, 2019	AB	RX	No	No
Breckenridge	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	209063-002	Nov 26, 2019	AB	RX	No	No
Amneal	METHYLPREDNISOLONE	methylprednisolone	TABLET;ORAL	207481-001	Sep 21, 2021		DISCN	No	No
Zydus Pharms	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	206318-001	Mar 4, 2019	AB	RX	No	No
Yichang Humanwell	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	215445-001	Sep 23, 2025	AB	RX	No	No
Mylan Technologies	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	205622-001	Jun 20, 2018	AB	RX	No	No
Pfizer	MEDROL	methylprednisolone	TABLET;ORAL	011153-002	Approved Prior to Jan 1, 1982		RX	Yes	No

Market dynamics and patent landscape for neuroprotective agents (MeSH) in the US, EU, and key emerging markets

Last updated: June 22, 2026

Neuroprotective agents are a fragmented therapeutic set with high patent heterogeneity across indications (Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury, multiple sclerosis, neuropathic pain, epilepsy, and ischemic injury). Patent estates are often indication-specific (method-of-use, patient selection, combination regimens) with formulation and device-like delivery IP that can outlast first composition-of-matter. Near-term market risk for branded incumbents concentrates around (1) patent expirations plus exclusivity cliffs in symptomatic neurology products, and (2) biosimilar entry for MS-related neuroinflammatory pathways where those products are classified within “neuroprotective” adjacency. The most defensible portfolios are those with layered claim coverage: composition or salt form plus dosing regimens, plus stable manufacturing and oral/sustained-release formulation IP.

What patents protect neuroprotective agents (MeSH neuroprotective agents) in 2026?

Short answer: Patents protecting “neuroprotective” products are most commonly layered across active ingredient IP, second-generation formulations (salt, polymorph, solid state form, particle size, release profile), and method-of-use claims (dose, titration, combination therapy, biomarker-defined patient populations).

Which MeSH “neuroprotective” categories drive patenting activity?

MeSH “Neuroprotective Agents” is a high-level umbrella. In practice, patent-heavy activity clusters in:

• Alzheimer’s disease: symptomatic cholinesterase inhibitors and NMDA antagonism, with newer disease-modifying programs (antibody and small-molecule approaches).
• Parkinson’s disease: neurotrophic and symptomatic regimens, including adjunct therapies and sustained exposure formulations.
• Stroke and ischemic injury: acute neuroprotection is claim-intensive on timing windows and combination use.
• Multiple sclerosis (MS) and neuroinflammation: neuroprotective effect via immunomodulation, with biosimilar-relevant biologic estates.
• Traumatic brain injury (TBI) and post-acute neuroprotection: method-of-use, delivery route, and dosing schedule patents.
• Epilepsy and neuroexcitotoxicity-adjacent agents: receptor-targeted compounds with dosing method claim sets.

Patent claim types seen most often in neuroprotection portfolios

• Composition-of-matter: parent drug, active metabolite, salt.
• Solid-state and formulation: polymorph/salt form, crystalline form, amorphous content, particle size distribution.
• Controlled release: matrix implants, depot injections, extended-release oral formulations.
• Method-of-use: treating neurodegeneration; time-from-onset windows; combination regimens (with antithrombotics, anti-inflammatories, or dopaminergic drugs).
• Patient selection: biomarker-defined responder populations and dose adjustment algorithms.
• Manufacturing methods: process parameters tied to yield, impurity profile, and stability.

Jurisdictional patterns

• US: stronger leverage for method-of-use claims and process patents; patent term adjustments can extend effective exclusivity on filing strategies.
• EU: Supplementary Protection Certificates (SPCs) and national proceedings can extend effective duration depending on first authorization date and compliance.
• Emerging markets: availability of secondary patents varies, and enforcement differs sharply by country.

When does neuroprotective drug exclusivity end and how do patent expirations stack?

Short answer: Exclusivity cliffs for “neuroprotective agents” rarely come from one date. They typically stack from (1) patent expiry of first and second-generation IP layers, (2) 5-year US exclusivity for new biologics/NDAs where applicable, (3) 6-month pediatric extensions, and (4) EU SPC expiry.

Typical exclusivity structure for neuroprotective products (US and EU)

• US:
  • Patent term end is driven by earliest non-provisional filing plus adjustments.
  • Orange Book listing supports statutory exclusivity, including 5-year New Chemical Entity (NCE) or 3-year NDA exclusivity (when applicable).
  • Pediatric extension can extend patents listed in the NDA.
• EU:
  • SPC duration depends on the regulatory authorization timing and product.
  • Data exclusivity for new actives and marketing authorization rights can lag patent filing strategy.

Patent stacking is common in layered neuroprotective portfolios

For many neuroprotective brands, the “last protection” is not composition-of-matter. It is often:

• controlled-release formulation patents,
• crystalline or polymorphic solid-state claims,
• method-of-use claims tied to dosing titration or timing.

Launch risk calendar logic used by challengers

Generic and biosimilar challengers map:

1. Earliest composition-of-matter expiry
2. Next formulation patent expiry
3. Method-of-use patent expiry
4. Any SPC expiry
5. Whether a Paragraph IV or biosimilar challenge can carve around remaining claims
6. Whether exclusivity bar applies independent of patents

Which companies control the neuroprotective patent estate?

Short answer: Control is split by modality. Large pharma dominates branded small molecules and biologics in MS and neurodegeneration; specialty neurology and generics dominate the tail end via reformulations and biosimilar adoption once biologics lose primary exclusivity.

Company patterns by therapeutic “neuroprotective” pathway

• MS neuroinflammation (biologics): biologic innovators and their life-cycle management units hold the strongest estates through device-like delivery and method-of-use claims.
• Alzheimer’s and neurodegenerative oncology-like modality: antibody and small-molecule programs show the longest claim duration from layered patents, including manufacturing and epitope-binding variants.
• Stroke/TBI acute neuroprotection: smaller innovators frequently rely on narrow method-of-use claims with timing windows.
• Parkinson’s adjunct/symptom management: incumbents often hold extended-release or combination regimen patents.

What formulations are protected by neuroprotective drug patents?

Short answer: For neuroprotective agents, the most durable IP is frequently formulation and delivery protection: extended-release profiles, salt/polymorph selection, and stability-linked manufacturing claims.

Formulation patent themes most relevant to generic entry

• Extended-release oral solids: matrix composition, coating parameters, release kinetics targets.
• Depot injections: particle size, polymer matrix, and injection protocol.
• Topical or transdermal (in neuro-related pain and adjunct neuroprotection adjacency): permeation enhancers and controlled absorption claim sets.
• Ocular and intrathecal delivery in neuro-adjacent programs: delivery route and device interfaces.

Typical “generic carve-out” strategy

Generic entrants often attempt to:

• use a different salt form or solid-state form,
• change release kinetics profile,
• change dosing regimen and titration steps,
• use a different delivery device or route if not claim-covered.

What patent litigation affects neuroprotective agents and what outcomes drive generic timing?

Short answer: Litigation risk is concentrated in Paragraph IV challenges tied to method-of-use and formulation patents. Settlement agreements frequently delay generic entry by defined periods and sometimes lock in “design-around” formulations.

Key litigation mechanics used in neuroprotective disputes

• Paragraph IV: triggers FDA approval timing leverage but does not end when patents are narrow. If any listed patent is not designed around, entry is barred.
• Claim construction fights: courts often narrow scope of method-of-use claims around specific dose ranges or patient selection.
• Validity challenges: obviousness based on prior art dosing and formulation disclosures are common where claim sets are broad.
• Injunction bargaining: settlement terms often reflect the probability of success and the expected end of the patent stack.

Settlement agreements: why they matter commercially

Because neuroprotective products have multiple listed patents, settlements typically:

• align with the last-remaining patent in the stack,
• extend exclusivity through partial “at-risk” launch constraints,
• define whether a generic must avoid specific claim parameters (dose, titration, release profile).

What is the Orange Book status of neuroprotective drugs?

Short answer: Orange Book listings typically show multiple listed patents for one neuroprotective NDA, spanning composition, method-of-use, and formulation. The “status” that matters to launch planning is the earliest “trigger date” among listed patents plus any statutory exclusivity.

How to read Orange Book signals for neuroprotective competitors

• Number of listed patents: more indicates a thicker claim stack and higher launch friction.
• Patent types: if multiple “drug product” and “method-of-use” patents are listed, challengers often face settlement or at-risk design-around.
• Expiration pattern: clustered expirations near one another can increase leverage for incumbents to extract settlements.

What generic entry risks exist for neuroprotective agents?

Short answer: Generic risk rises when the patent stack includes weak formulation claims and when method-of-use claims are narrow enough to design around via dosing or patient selection. It falls when controlled-release or solid-state claims remain unexpired and cover key commercial dosing forms.

Generic entry risk matrix (qualitative)

Portfolio characteristic	Higher generic risk	Lower generic risk
Patent stack depth	Sparse listings	Many listed patents across drug product and methods
Claim type	Composition-only, weak method claims	Formulation + method + process layered claims
Design-around feasibility	Many alternative salts/forms	One-to-one linkage of claims to commercial dosage
Litigation status	No active suits	Ongoing or recently settled actions show entrenched positions
Regulatory posture	Uncomplicated labeling	Label-driven method-of-use constraints

How do neuroprotective agents compare with similar neuro-related categories (neurodegeneration, neuroinflammation, neuropathic pain)?

Short answer: Patent estate strength differs by clinical endpoint. Symptomatic neurodegeneration often has shorter high-value exclusivity windows than biologic neuroinflammation, where SPC and biologic-specific rules extend effective exclusivity.

Category comparison lens

• Neurodegeneration (Alzheimer’s/Parkinson’s): method-of-use and biomarker selection are common; formulation patents can be durable.
• Neuroinflammation (MS): biologic estates plus delivery technology and manufacturing process patents can extend the stack.
• Neuropathic pain: often dominated by small-molecule chemistry and formulation differentiation (extended-release, prodrug forms).

Where are the biggest revenue exposures from patent cliffs in neuroprotective agents?

Short answer: Revenue exposure concentrates in brands with (1) multi-patent Orange Book listings, (2) active Paragraph IV history, or (3) imminent formulation or method-of-use expiry. The highest exposure typically sits in the US due to Orange Book-driven litigation leverage and regulatory timelines.

Commercial timing factors that amplify patent cliff impact

• US Hatch-Waxman timing: Paragraph IV litigations can force “60-day notice” and define launch timing windows.
• EU SPC lag: protects the product later than US patents when authorization dates support SPC eligibility.
• Regional variation: some incumbents maintain market share through labeling differences and manufacturing scale rather than pure patent defense.

Biosimilar risk for neuroprotective biologics: what changes after exclusivity?

Short answer: For biologic neuroinflammation or neuroprotection-adjacent agents, biosimilar entry risk is driven by biosimilar-specific exclusivity and the remaining patent stack. Once primary exclusivity ends, the remaining patent estate is frequently decisive.

Biosimilar entry risk drivers

• Remaining patents are often process and formulation-linked: manufacturing and glycosylation profile claims can slow “drop-in” equivalency.
• Method-of-use claims can constrain labeling: biosimilars may launch but with narrower indication language.
• Patent settlements: commonly define launch date and product interchangeability language.

Which “neuroprotective agent” programs face the highest competitive pressure?

Short answer: Competitive pressure is highest where the original product has (a) a large claimed indication scope, (b) publicly described dosing regimens that are easy to replicate, and (c) formulation differentiation that can be designed around with a different release profile.

Pressure patterns by modality

• Small molecules: generics can enter quickly when method claims are narrow or not listed.
• Biologics: biosimilars face slower resolution due to manufacturing and process patents, but once resolved, entry can be rapid across US/EU.
• Acute neuroprotection: fewer generic entrants due to claim narrowness and tight clinical trial endpoints tied to label language.

Key Takeaways

1. Neuroprotective agents have high patent heterogeneity; durable protection is most often formulation and method-of-use, not only composition-of-matter.
2. Patent cliffs are stacked: generic and biosimilar launch timing depends on the last unexpired listed patent and the intersection with statutory exclusivities.
3. Orange Book strategy and Paragraph IV litigation are the primary commercial gates in the US, with SPC-driven extensions shaping EU timing.
4. Formulation and delivery patents (extended-release, depot, solid-state forms) are the most common practical barriers to design-around.
5. Biosimilar risk in neuroinflammation-adjacent biologics accelerates once primary exclusivity ends, but the remaining process and method-of-use patent stack typically governs whether label-full entry is possible.

FAQs

1) How many patents are typically listed for a single neuroprotective NDA in the Orange Book?
Neuroprotective NDAs often list multiple patents across drug substance, drug product, and method-of-use categories, creating a thicker “stack” than many purely symptomatic products.

2) What makes method-of-use patents more enforceable in neuroprotective litigation?
Method claims that closely track dosing regimens, patient selection, and label language are harder for challengers to design around without changing clinical labeling.

3) Do polymorph and solid-state patents materially affect generic launches for neuroprotective agents?
Yes when claims tie to specific solid-state forms used in commercial manufacturing and when the generic’s alternative form is not within the claim scope.

4) When do SPCs extend neuroprotective product exclusivity in the EU relative to US patents?
SPCs can extend effective protection when EU authorization and first authorization dates support eligibility, shifting the EU cliff later than the US.

5) What settlement terms are most common in neuroprotective Paragraph IV cases?
Settlements often delay launch until a defined “last patent” date and include design-around boundaries on labeling, dosing, and formulation parameters.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-22).
2. European Medicines Agency. Supplementary Protection Certificates (SPC) information and guidance. (Accessed 2026-06-22).
3. FDA. Hatch-Waxman Act and exclusivity provisions (statutory framework). (Accessed 2026-06-22).